Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: A randomized pilot study

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 3, 2003, Pages 464-468

  Laguna, Fernando ^a   Videla, Sebastián ^b   Jiménez Mejías, Manuel E ^c   Sirera, Guillem ^d   Torre Cisneros, Julián ^e   Ribera, Esteban ^f   Prados, Dolores ^c   Clotet, Bonaventura ^d   Sust, Mariano ^b   López Vélez, Rogelio ^g   Alvar, Jorge ^h   Viciana, Pompeyo ^c   Navarro, Tomás ^d   Kindelán, José M ^e   Azuaje, Carlos ^f   Altés, Jordi ⁱ   Arribas, José R ^a   Boix, Vicente ^j   Gatell, Josep M ^k   de Górgolas, Miguel ^l   Márquez, Manuel ^m   Pulido, Federico ⁿ   Rubio, Rafael ⁿ   Salas, Ana ^o   Sanz, Jesús ^p   Cañavate, Carmen ^q   Chicharro, Carmen ^q   Cruz, Israel ^q   Morales, Miguel A ^q   Casals, Soledad ^b   García, Carmen ^b   Sanz, Artur ^b   Puyada, Alberto ^b   Tolrà, Ignasi ^b   more..

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Laboratorios Dr Esteve SA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ Hospital Comarcal de L'Alt Penedes   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^p HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^q INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Anti leishmanial drugs; Clinical trials; Leishmania

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; MEGLUMINE ANTIMONATE;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERAMYLASEMIA; HYPOKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PHLEBITIS; PILOT STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING;

ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BONE MARROW; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 10744227879     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg356     Document Type: Article

References (25)

1. Alvar, J., Cañavate, C., Gutiérrez-Solar, B. et al. (1997). Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiological Review 10, 298-319.
2. Herwaldt, B. L. & Berman, J. D. (1992). Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene 46, 296-306.
3. Herwaldt, B. L. (1999). Leishmaniasis. Lancet 354, 1191-9.
4. Laguna, F., López-Vélez, R., Pulido, F. et al. (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomised trial comparing meglumine antimoniate with amphotericin B. AIDS 13, 1063-9.
5. Janoff, A. S., Perkins, W. R., Saletan, S. L. et al. (1993). Amphotericin B lipid complex (ABLCTM): a molecular rationale for the attenuation of amphotericin B related toxicities. Journal of Liposome Research 3, 451-71.
6. Boswell, G. W., Buell, D. & Bekersky. I. (1998). AmBisome (liposomal amphotericin B): a comparative review. Journal of Clinical Pharmacology 38, 583-92.
7. Berman, J. D., Hanson, W. L., Chapman, W. L. et al. (1986). Antileishmanial activity of liposome encapsuled amphotericin B in hamsters and monkeys. Antimicrobial Agents and Chemotherapy 30, 847-51.
8. Sundar, S., Agrawal, N. K., Sinha, P. R. et al. (1997). Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Annals of Internal Medicine 127, 133-7.
9. Davidson, R. N., Di Martino, L., Gradoni, L. et al. (1994). Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicenter trial. Quarterly Journal of Medicine 87, 75-81.
10. Sundar, S. & Murray, H. W. (1996). Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. Journal of Infectious Diseases 173, 762-5.
11. Sundar, S., Agrawal, G., Rai, M. et al. (2001). Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. British Medical Journal 323, 419-22.
12. Russo, R., Nigro, L. C., Minniti, S. et al. (1996). Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). Journal of Infection 32, 133-7.
13. Torre-Cisneros, J., Villanueva, J. L. & Kindelan, J. M. (1993). Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 17, 625-7.
14. Laguna, F., Torre-Cisneros, J., Moreno, V. et al. (1995). Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 21, 711-2.
15. Morales, M. A., Cruz, I., Rubio, J. M. et al. (2002). Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. Journal of Infectious Diseases 185, 1533-7.
16. Tumbarello, M., Tacconelli, E., Bertagnolio, S. et al. (2000). Highly active antiretroviral therapy decreases incidence of visceral leishmaniasis in HIV-infected individuals. AIDS 14, 2948-9.
17. López Vélez, R., Casado, J. L. & Pintado, V. (2001). Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clinical Microbiology and Infection 7, 394-5.
18. López-Vélez, R., Pérez Molina, J. A., Guerrero, A. et al. (1998). Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmaniasis in an area of Madrid, Spain. American Journal of Tropical Medicine and Hygiene 58, 436-43.
19. Medrano, F. J., Hernández-Quero, J., Jiménez, E. et al. (1992). Visceral leishmaniasis in HIV-infected individuals: a common opportunistic infection in Spain? AIDS 6, 1499-503.
20. Montalban, C., Calleja, J. L., Erice, A. et al. (1990). Visceral leishmaniasis in patients infected with human immunodeficiency virus. Journal of Infection 21, 261-70.
21. Laguna, F., Adrados, M., Alvar, J. et al. (1997). Visceral leishmaniasis in patients infected with the human immunodeficiency virus. European Journal of Clinical Microbiology and Infectious Diseases 16, 898-903.
22. Pintado, V., Martín-Rabadán, P., Rivera, M. L. et al. (2001). Visceral leishmaniasis in human-immunodeficiency virus (HIV)-infected and non-HIV-infected patients. Medicine 80, 54-73.
23. Gradoni, L., Bryceson, A. & Desjeux, P. (1995). Treatment of mediterranean visceral leishmaniasis. Bulletin of the World Health Organisation 73, 191-7.
24. Aronson, N. E., Wortmann, G. W., Johnson, S. C. et al. (1998). Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U. S. military experience. Clinical Infectious Diseases 27, 1457-64.
25. Berman, J. D., Badaró, R., Thakur, C. P. et al. (1998). Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of the World Health Organisation 76, 25-32.